Vium is a biotechnology company that develops digital biomarkers to transform preclinical research and animal welfare.
Vium is a biotechnology company that develops digital biomarkers to transform preclinical research and animal welfare. It is fully accredited by AAALAC International and received an unprecedented AAALAC commendation for upholding the 3 Rs, the gold-standard framework for humane animal research. Customers run the spectrum of biotechnology, pharmaceutical, and computational drug discovery companies to academia and novel therapeutic labs.Vium's digital platform provides physiological biomarkers that enable better decisions on which compounds should be advanced to the clinic. The company's platform Digital Vivariumand Vium Cloud is the gold-standard in vivo platform combining computer vision, artificial intelligence, machine learning, and sensor technology to non-invasively collect and derive insights from digital biomarkers. The platform continuously captures physiological metrics and behaviors non-invasively, providing more sensitive and accurate data collection, leading to more replicable studies.Vium was founded in 2013 and is headquartered in San Mateo, California, United States.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 21, 2018 | Series B | $24M | 5 | DCVC Lux Capital | — | Detail |
Jun 9, 2015 | Series A | $20M | 5 | — | — | Detail |
Oct 29, 2014 | Series A | $8.80M | 4 | Proteus Digital Health | — | Detail |
Mar 1, 2014 | Seed | $1.14M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
DCVC | Yes | Series B |
Lux Capital | Yes | Series B |
Proteus Digital Health | Yes | Series A |
Dolby Family Ventures | — | Series B |
Founders Fund | — | Series B |
Future Shape | — | Series B |
AME Cloud Ventures | — | Series A |
Jim Greer | — | Seed |
Pathfinder | — | Seed |